Anacor Pharmaceuticals (NASDAQ:ANAC)

CAPS Rating: 1 out of 5


Player Avatar zzlangerhans (99.85) Submitted: 4/3/2013 12:59:45 AM : Underperform Start Price: $6.19 ANAC Score: +12.75

As predicted, in March the stock rebounded from the weak phase III performance of tavaborole with positive results from dose-ranging phase II trial of AN2728 in atopic dermatitis. But 220M is simply too much for a phase II drug in the crowded indication of atopic dermatitis. Anacor will certainly raise big before getting close to topline data from a phase III trial of AN2728, and approval of Valeant's efinaconazole in May will provide another nail for tavaborole's coffin.

Featured Broker Partners